NAV
530.35(0.35%)Fund Size (CR)
₹8,365.4Expense Ratio
2.32Scheme Type
Active FundValue Research
-
Min. investment
₹5,000Minimum Additional Investment
₹1,000Minimum SIP Investment
₹Minimum Withdrawal
₹100Exit Load
1%Return Since Launch
19.76%
Basic Details
Scheme Manager
Sailesh Raj Bhan
Bench Mark
BSE Healthcare TRI
Type
OPEN
Lumpsum Returns
| Period Invested For | ₹10,000 Invested on | Latest Value | Absolute Returns | Annualised Returns | Category Avg | Rank within Category |
|---|---|---|---|---|---|---|
| 1 Week | May 26, 2026 | 9788.43 | -2.12% | - | -1.26% | 763/1007 |
| 1 Month | April 30, 2026 | 10221.41 | 2.21% | - | 0.63% | 290/1007 |
| 3 Month | March 2, 2026 | 10305.26 | 3.05% | - | 2.00% | 401/991 |
| 6 Month | December 2, 2025 | 10252.91 | 2.53% | - | -1.18% | 282/956 |
| 1 Year | June 2, 2025 | 10493.54 | 4.94% | 4.94% | 4.80% | 346/872 |
| 3 Year | June 2, 2023 | 17890.81 | 78.91% | 21.38% | 17.09% | 146/530 |
| 5 Year | June 2, 2021 | 17921.35 | 79.21% | 12.37% | 14.42% | 266/434 |
| Since Inception | June 5, 2004 | 528511.30 | 5185.11% | 19.76% | 10.42% | 99/1007 |
Note: Lumpsum Returns since Inception Date.
SIP Returns
| Period Invested For | ₹10,000 Invested on | Investments | Latest Value | Absolute Returns | Annualised Returns |
|---|---|---|---|---|---|
| 1 Year | July 1, 2025 | 1,20,000 | 124719.37 | 3.93% | 3.93% |
| 3 Year | July 3, 2023 | 3,60,000 | 421432.70 | 17.06% | 5.39% |
| 5 Year | July 1, 2021 | 6,00,000 | 864228.39 | 44.04% | 7.57% |
| 10 Year | July 1, 2016 | 12,00,000 | 2911541.24 | 142.63% | 9.27% |
Note: SIP Returns since Inception Date.
Tax Treatment
If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 10%, if your total long term capital gain exceeds 1 lakh. Any cess/surcharge is not included.If sold before 1 year from purchase date, short term capital gain tax will be applicable. Current tax rate is 15%. Any cess/surcharge is not included in the 15%.
Mutual Funds Calculator
Monthly Investment (₹)
Expected Returns Rate (%)
Time Period (in Years)
Invested Amount
₹25,000
Estimated Returns
₹19,059
76%
Returns
Future value of your investment
₹44,059
Risk Ratios
4.53%
Standard Deviation
0.75%
Beta
0.90%
Sharpe Ratio
0.00%
Treynor's Ratio
13.76%
Jension's Alpha
Asset Allocation
Sector Allocation
Top 10 stock holding in portfolio
| Stock Invested in | % of Total Holdings | Quantity | Value (Cr) | Asset Type | Segment |
|---|---|---|---|---|---|
| Sun Pharma.Inds. | 13.85% | 6406349 | 1158.46 | Equity | Pharmaceuticals |
| Lupin | 7.95% | 2883991 | 664.82 | Equity | Pharmaceuticals |
| Dr Reddy's Labs | 7.04% | 4449746 | 588.66 | Equity | Pharmaceuticals |
| Divi's Lab. | 6.61% | 850754 | 553.20 | Equity | Pharmaceuticals |
| Cipla | 5.47% | 3495054 | 457.71 | Equity | Pharmaceuticals |
| Apollo Hospitals | 5.01% | 548795 | 419.09 | Equity | Healthcare |
| Medplus Health | 3.78% | 3627277 | 316.35 | Equity | Retail |
| Vijaya Diagnost. | 3.36% | 2486684 | 280.90 | Equity | Healthcare |
| Sai Life | 3.27% | 2555745 | 273.32 | Equity | Pharmaceuticals |
| Ajanta Pharma | 3.19% | 946323 | 267.12 | Equity | Pharmaceuticals |
Peer Comparison
| Scheme Name | Value Research | Asset Size (Cr) | 1M | 3M | 6M | 1Y | 3Y |
|---|---|---|---|---|---|---|---|
| Nippon India Taiwan Equity Fund - Direct (G) | 1138.67 | 11.96% | 64.59% | 117.75% | 230.82% | 65.82% | |
| Nippon India Taiwan Equity Fund - Direct (IDCW) | 1138.67 | 11.96% | 64.59% | 117.75% | 230.82% | 65.82% | |
| Franklin Asian Equity Fund - Direct (G) | 520.57 | 13.14% | 15.13% | 31.55% | 57.50% | 22.74% | |
| Franklin Asian Equity Fund - Direct (IDCW) | 520.57 | 13.14% | 15.13% | 31.55% | 57.48% | 22.73% | |
| Nippon India Japan Equity Fund - Direct (G) | 329.73 | 6.58% | 5.13% | 21.88% | 35.54% | 20.58% |
List of Schemes under Nippon India Mutual Fund
News
Nippon India Mutual Fund announces Ceasation of Key Personnel
Nippon India Mutual Fund Announces Cessation of Key Personnel Mr. Rajesh K. Derhgawen, Chief Human Resource Officer has ceased from the services of Nippon Life India Asset Management Limited due to his superannuation with effect from May 31, 2026. Accordingly, the details pertaining to Mr. Rajesh K. Derhgawen shall stand deleted in SAI under the para titled 'Information on Key Personnel'.Powered by Capital Market - Live News
Nippon India Mutual Fund announces Appointment of Key Personnel
Nippon India Mutual Fund has announced that Mr. Mohit Shankar Shetty, Deputy Chief Human Resource Officer has been redesignated as Chief Human Resource Officer with effect from June 01, 2026. Accordingly, he has been designated as Key personnel and following details pertaining to Mr. Shetty shall be incorporated in SAI under the para titled 'Information on Key Personnel'.Name: Mr. Mohit Shankar Shetty
Age: 51 years
Designation: Chief Human Resource Officer
Qualification: B.com, MBA- HRM
Powered by Capital Market - Live News
Nippon India Fixed Maturity Plan ' XLV ' Series 5 announces Rollover
Nippon India Mutual Fund has decided to rollover the maturity of following Fixed Maturity Plans, with immediate effectAccordingly, the proposed changes will be:
Scheme Name Tenure Existing Maturity Date Rollover tenure Revised maturity date Nippon India Fixed Maturity Plan ' XLV ' Series 5 1158 Days June 01, 2026 1156 Days July 31, 2029 Powered by Capital Market - Live News
Fund House Details & Investment Objective
Date of Incorporation
May 10, 2004
Total AUM (Cr)
₹8365.40
Nippon India Pharma Fund (Bonus) is an Sectoral / Thematic-oriented fund from the renowned AMC, Nippon India Mutual Fund. Launched in May 10, 2004, this fund is managed by Sailesh Raj Bhan. With assets under management (AUM) worth ₹8,365.4 (Cr), as of June 3, 2026, Nippon India Pharma Fund (Bonus) is categorized as a Sectoral / Thematic within its segment. The fund has generated a return of 19.76% since its launch.
The current NAV of Nippon India Pharma Fund (Bonus) is ₹530.35, as on June 3, 2026. The fund's benchmark index is BSE Healthcare TRI. You can invest in Nippon India Pharma Fund (Bonus) via both lumpsum and SIP modes. The minimum SIP amount in the fund is - while the minimum lumpsum investment is ₹5,000.
Being an open-ended fund, you can exit the fund anytime subject to applicable exit loads:
The fund has generated 21.38% and 12.37% CAGR in the last 3 and 5 years respectively.
The fund aims to provide long-term capital appreciation and growth, by investing in a mix of financial instruments 98.70% in Equity, 0.86% in Debt and 0.44% in cash and cash equivalents.
The top 5 sectors the fund invests in are: 75.26% in Pharmaceuticals & Biotech, 20.33% in Healthcare Services, 3.86% in Retailing, 0.86% in Debt, -0.31% in Cash & Others
Mutual Fund Categories
Types of Mutual Funds
Debt Funds
Access debt markets and enjoy interest income from bonds and debentures. Ideal for conservative short-term investors
Hybrid Funds
Enjoy best of both the worlds - equity and debt. Ideal for beginners with medium-term investment horizon
Equity Funds
Invest in large, mid, and small cap sector stocks to enjoy capital appreciation. Ideal for aggressive, long-term investors